ImmunoPrecise Antibodies (OTCMKTS:IPATF) Shares Up 5.9% – Should You Buy?

Shares of ImmunoPrecise Antibodies Ltd. (OTCMKTS:IPATF) traded up 5.9% during mid-day trading on Wednesday . The stock traded as high as $1.50 and last traded at $1.44. Approximately 445,607 shares changed hands during mid-day trading, an increase of 2,092% from the average daily volume of 20,327 shares. The stock had previously closed at $1.36.

ImmunoPrecise Antibodies Price Performance

The business’s 50-day simple moving average is $1.56 and its 200 day simple moving average is $1.49.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) is a Canada-based contract research organization specializing in the discovery and development of therapeutic antibodies. The company provides a full suite of preclinical research services, from target validation and lead identification through to humanization and optimization. Its capabilities encompass hybridoma, phage display, single B cell sorting and next-generation sequencing platforms to accelerate antibody candidate selection and characterization.

ImmunoPrecise serves biopharmaceutical and biotechnology partners worldwide, offering customized solutions for projects in immuno-oncology, infectious diseases, autoimmunity and other therapeutic areas.